#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    IPEX syndrome Spinal muscular atrophy Bulbospinal muscular atrophy congenital Pemphigoid Hypersensitivity pneumonitis SAPHO syndrome Sickle cell disease Transient ischaemic attack Arrhythmogenic right ventricular dysplasia Peritoneal neoplasm Ewing's sarcoma recurrent Cytomegalovirus infection Acute myeloid leukaemia Vaginal cancer Acute graft versus host disease More trials…

    Learn about Rare Diseases

    Mast cell activation syndrome – Treatment Alexander disease – Diagnostics Mantle cell lymphoma – Diagnostics Lymphatic malformation Focal segmental glomerulosclerosis – Diagnostics Acute respiratory distress syndrome – Treatment Ornithine transcarbamoylase deficiency Osteosarcoma – Life with Disease Waldenstrom’s macroglobulinaemia recurrent – Diagnostics Malignant fibrous histiocytoma – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Litifilimab Tanimilast Lorazepam AMODIAQUINE Ro7790121 Repotrectinib Ioversol Amisulpride Msv-Allo Fluorouracil Bimekizumab Clindamycin Phosphate Tetracosactide Diclofenac Sodium Tipranavir Perflutren Relacorilant Piperacillin Monohydrate Tazobactam Sodium Infigratinib More therapies…

    Learn about Your Condition

    Combined immunodeficiency Cardiac failure Ocular lymphoma Pulmonary congestion Breast cancer stage III Non-small cell lung cancer Pyoderma gangrenosum Microvillous inclusion disease Albuminuria Influenza Right ventricular dysfunction Rectal cancer Mitral valve prolapse Extraskeletal ossification Gender dysphoria More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Diagnostics And Consultation Center Convex Ltd.

Diagnostics And Consultation Center Convex Ltd.

Ulitsa Sinanishko Ezero 11a, Sofia, 1680, Bulgaria

Want to learn more about this study or check if you can participate? Contact us.

  • A Study of Depemokimab Compared to Placebo in Adults with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation

    Recruiting

    3 1 1
    Investigated Drugs:
    • Depemokimab
    • Salbutamol Sulfate
    Austria Bulgaria Czechia Germany Greece Italy +2

  • Phase IIb Study of AZD8965 versus Placebo in Adults with Idiopathic Pulmonary Fibrosis

    Recruiting

    2 1
    Investigated Diseases:
    • Idiopathic pulmonary fibrosis
    Bulgaria Denmark France Germany Greece Hungary +4

  • Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

    Recruiting

    3 1 1
    Investigated Drugs:
    • Golimumab
    • Guselkumab
    Austria Belgium Bulgaria Czechia Denmark France +11

  • A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis

    Recruiting

    3 1
    Austria Belgium Bulgaria Croatia Czechia Denmark +16

  • Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Durvalumab
    Austria Belgium Bulgaria France Germany Greece +8

  • Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

    Recruiting

    3 1
    Austria Belgium Bulgaria Croatia Czechia Denmark +14

  • Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Pembrolizumab
    Austria Belgium Bulgaria Czechia Finland France +10

  • GB-0895 for Severe Uncontrolled Asthma in Adults and Adolescents

    Recruiting

    3 1
    Bulgaria Croatia Czechia Germany Greece Hungary +4

  • Study to evaluate the efficacy and safety of deucrictibant for the prevention and treatment of angioedema attacks in adults with acquired angioedema

    Recruiting

    3 1
    Investigated Drugs:
    • Deucrictibant
    Austria Bulgaria France Germany Hungary Italy +3

  • A study of the humanised IgG1 lalaps-yte monoclonal antibody against lysophosphatidic acid receptor 1 to treat adults with idiopathic pulmonary fibrosis

    Recruiting

    2 1
    Investigated Drugs:
    • HUMANISED IGG1 LALAPS-YTE MONOCLONAL ANTIBODY AGAINST LYSOPHOSPHATIDIC ACID RECEPTOR 1
    Bulgaria France Germany Greece Hungary Italy +5
1 2 3 … 10
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!